NEW YORK, Aug. 14, 2013 /PRNewswire/ — The Tisch MS Research Center of New York announced today that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to commence a Phase 1 trial using autologous neural stem cells in the treatment of multiple sclerosis (MS). MS is a chronic human autoimmune disease of the central nervous system that leads to myelin damage and neurodegeneration and affects approximately 2.1 million people worldwide.
“To my knowledge, this is the first FDA-approved stem cell trial in the United States to investigate direct injection of stem cells into the cerebrospinal fluid of MS patients, and represents an exciting advance in MS research and treatment,” said Dr. Saud A. Sadiq, Senior Research Scientist at Tisch MS Research Center of New York and the study’s principal investigator.
The groundbreaking study will investigate a regenerative strategy using stem cells harvested from the patient’s own bone marrow. These stem cells will be injected intrathecally (into the cerebrospinal fluid surrounding the spinal cord) in 20 participants who meet the inclusion criteria for the trial. This will be an open label safety and tolerability study. All study activities will be conducted at the Tisch MS Research Center and affiliated International Multiple Sclerosis Management Practice (IMSMP).
……..
To comment – click the comment link shown below
…….
USE OUR SHARE LINKS at the top of this page – to provide this
article to others
…….
USE OUR SHARE LINKS at the top of this page – to provide this
article to others
……
REMAIN up to date
with MS News and Education
with MS News and Education
Visit: www.msviewsandnews.org to register
…………………….
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews